Alex Galbraith

Alex is a patent attorney working in our life sciences team. He has experience working with both local and international clients, assisting with a range of patent matters such as drafting of patent applications related to antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates, and prosecution of patent applications before the UKIPO and the EPO.

He also has experience working on large multi-party oppositions and appeals before the EPO relating to antibody-based therapeutics and antibody production methods involving multinational biopharmaceutical clients, as well as assisting with Freedom to Operate and validity opinions.

Areas of Expertise

Biotechnology, with a special interest in:

• Gene editing, particularly CRISPR-based editing technologies such as base editing and prime editing
• Cell and gene therapies
• Antibody-based therapeutics, particularly antibody-drug conjugates and novel antibody formats
• Cancer therapeutics and biomarkers
• Antibody production methods

Background

Alex has a BSc degree in Biological Sciences from Durham University where he was awarded the Biological Sciences Prize. He also gained industrial experience working with CRISPR base editing technology within a large pharmaceutical company during his degree. 

Alex joined Mewburn Ellis in 2020 and qualified as a Chartered Patent Attorney in 2024.